Foghorn Therapeutics Inc.
NASDAQ:FHTX
4.43 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 22.602 | 34.155 | 19.228 | 1.319 | 0.43 | 0 | 0 |
| Cost of Revenue
| 0 | 109.689 | 0.019 | 7.515 | 57.715 | 1.793 | 0.379 |
| Gross Profit
| 22.602 | -75.534 | 19.209 | -6.196 | -57.285 | -1.793 | -0.379 |
| Gross Profit Ratio
| 1 | -2.212 | 0.999 | -4.697 | -133.221 | 0 | 0 |
| Reseach & Development Expenses
| 94.528 | 109.689 | 105.618 | 80.325 | 57.715 | 44.362 | 21.225 |
| General & Administrative Expenses
| 28.359 | 32.372 | 30.747 | 21.728 | 11.246 | 6.722 | 4.824 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.359 | 32.372 | 30.747 | 21.728 | 11.246 | 6.722 | 4.824 |
| Other Expenses
| 2.398 | 0 | 8.255 | 2.494 | 0 | 0 | 0 |
| Operating Expenses
| 125.285 | 142.061 | 136.365 | 102.053 | 68.961 | 51.084 | 26.049 |
| Operating Income
| -102.683 | -107.906 | -117.137 | -100.734 | -68.531 | -51.084 | -26.049 |
| Operating Income Ratio
| -4.543 | -3.159 | -6.092 | -76.371 | -159.374 | 0 | 0 |
| Total Other Income Expenses Net
| 16.063 | 13.706 | 8.255 | -0.586 | -0.269 | -0.044 | -0.288 |
| Income Before Tax
| -86.62 | -94.2 | -108.882 | -101.32 | -68.8 | -51.128 | -26.337 |
| Income Before Tax Ratio
| -3.832 | -2.758 | -5.663 | -76.816 | -160 | 0 | 0 |
| Income Tax Expense
| 0 | 4.226 | -0.008 | 1.906 | 0.979 | 0.54 | 0.083 |
| Net Income
| -86.62 | -98.426 | -108.874 | -103.226 | -69.779 | -51.668 | -26.337 |
| Net Income Ratio
| -3.832 | -2.882 | -5.662 | -78.261 | -162.277 | 0 | 0 |
| EPS
| -1.58 | -2.34 | -2.62 | -2.78 | -1.9 | -1.4 | -1.34 |
| EPS Diluted
| -1.58 | -2.34 | -2.62 | -2.78 | -1.9 | -1.4 | -1.34 |
| EBITDA
| -97.165 | -104.455 | -113.816 | -96.187 | -66.494 | -48.795 | -25.587 |
| EBITDA Ratio
| -4.299 | -3.058 | -6.092 | -71.989 | -153.96 | 0 | 0 |